Gylden Pharma
Developer of synthetic T cell‑priming vaccine and immunotherapy candidates. Focus areas include discovery and selection of MHC class I peptides (ligandome libraries), development of multi‑epitope synthetic T cell vaccines, and delivery system development (nanoparticles and microneedle platforms). Pipeline indications include betacoronaviruses, dengue, universal/pandemic influenza, chikungunya and other intracellular pathogens. The company collaborates with academic research institutes and participates in early‑phase clinical studies.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Pipeline of T cell‑priming vaccine candidates
A pipeline of synthetic T cell‑priming vaccine and immunotherapy candidates targeting betacoronaviruses, dengue, universal/pandemic influenza, chikungunya and intracellular bacterial pathogens.
Pipeline of T cell‑priming vaccine candidates
A pipeline of synthetic T cell‑priming vaccine and immunotherapy candidates targeting betacoronaviruses, dengue, universal/pandemic influenza, chikungunya and intracellular bacterial pathogens.
Services
Identification and preclinical evaluation of conserved peptide antigens and multi‑epitope vaccine constructs using immunopeptidomics and proteomics.
Development of nanoparticle formulations and microneedle delivery approaches for administration of synthetic peptide vaccines.
Management and operational support for Phase I clinical studies including clinical operations leadership.
Identification and preclinical evaluation of conserved peptide antigens and multi‑epitope vaccine constructs using immunopeptidomics and proteomics.
Development of nanoparticle formulations and microneedle delivery approaches for administration of synthetic peptide vaccines.
Management and operational support for Phase I clinical studies including clinical operations leadership.
Expertise Areas
- T‑cell priming vaccine development
- Immunopeptidomics and antigen discovery
- Proteomics and targeted mass spectrometry
- Nanoparticle and microneedle vaccine delivery
Key Technologies
- MHC class I peptide libraries / ligandome screening
- Immunopeptidomics
- Targeted mass spectrometry
- Label‑free quantitative proteomics
News & Updates
Press release outlining the company's strategic priorities for 2025.
Announcement regarding change of company name to reflect expanded technology and pipeline.
Press release reporting selection of a T cell‑priming vaccine candidate for betacoronaviruses for inclusion in an NIH/NIAID Project NextGen clinical trial initiative.
Article discussing the concept of cross‑reactive T cell vaccines and the potential for conserved peptide‑based vaccines to offer genus‑wide protection.
Media article describing the scientific approach to genus‑wide vaccine protection and related technology concepts.
Press release outlining the company's strategic priorities for 2025.
Announcement regarding change of company name to reflect expanded technology and pipeline.
Press release reporting selection of a T cell‑priming vaccine candidate for betacoronaviruses for inclusion in an NIH/NIAID Project NextGen clinical trial initiative.
Article discussing the concept of cross‑reactive T cell vaccines and the potential for conserved peptide‑based vaccines to offer genus‑wide protection.
Media article describing the scientific approach to genus‑wide vaccine protection and related technology concepts.